Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clin Cancer Res. 2023 Feb 28; OF1-OF7.
View in:
PubMed
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clin Cancer Res. 2023 Jan 20.
View in:
PubMed
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. J Clin Oncol. 2022 Dec 08; JCO2201826.
View in:
PubMed
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. JCO Precis Oncol. 2022 07; 6:e2200165.
View in:
PubMed
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2022 04 01; 8(4):579-586.
View in:
PubMed
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. Blood Cancer J. 2022 04 01; 12(4):53.
View in:
PubMed
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ Precis Oncol. 2022 Mar 01; 6(1):13.
View in:
PubMed
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 05 10; 40(14):1552-1561.
View in:
PubMed
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 02; 6:e2100424.
View in:
PubMed
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022 Jan 11; 8(1):3.
View in:
PubMed
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. Cancer. 2021 12 15; 127(24):4546-4556.
View in:
PubMed
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 01 15; 28(2):271-278.
View in:
PubMed
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer. 2022 Feb 01; 128(3):536-546.
View in:
PubMed
Reclassifying stroke lesion anatomy. Cortex. 2021 12; 145:1-12.
View in:
PubMed
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021 Jun 17.
View in:
PubMed
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. Ann Oncol. 2021 Aug; 32(8):1068.
View in:
PubMed
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. J Natl Cancer Inst. 2021 04 06; 113(4):390-399.
View in:
PubMed
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. Cancer. 2021 07 15; 127(14):2545-2552.
View in:
PubMed
Reply to K. Ando et al. J Clin Oncol. 2021 06 10; 39(17):1947-1948.
View in:
PubMed
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 06 01; 27(11):2996-3004.
View in:
PubMed
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol. 2021 02 01; 7(2):271-278.
View in:
PubMed
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. J Clin Oncol. 2021 02 20; 39(6):557-564.
View in:
PubMed
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
View in:
PubMed
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
View in:
PubMed
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020 11 20; 38(33):3895-3904.
View in:
PubMed
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 07 20; 38(21):2407-2417.
View in:
PubMed
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. 2020 06 10; 38(17):1875-1886.
View in:
PubMed
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 03 01; 6(3):367-374.
View in:
PubMed
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clin Cancer Res. 2020 04 15; 26(8):1812-1819.
View in:
PubMed
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 Nov; 30(11):1821-1830.
View in:
PubMed
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222.
View in:
PubMed
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 11 01; 30(11):1821-1830.
View in:
PubMed
Noninferiority trials with nonadherence to the assigned randomized treatment. Clin Trials. 2019 12; 16(6):673-681.
View in:
PubMed
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz062.
View in:
PubMed
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz050.
View in:
PubMed
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz049.
View in:
PubMed
TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. J Clin Oncol. 2019 07 20; 37(21):1841-1842.
View in:
PubMed
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405.
View in:
PubMed
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 03 01; 37(7):559-569.
View in:
PubMed
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1360-1369.
View in:
PubMed
Pragmatic approaches to address expansion cohort design. Cancer. 2018 08; 124(16):3290-3292.
View in:
PubMed
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):111-121.
View in:
PubMed
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018; 4:1.
View in:
PubMed
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer. 2017; 3:42.
View in:
PubMed
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. JCO Precis Oncol. 2017; 1.
View in:
PubMed
The EFCR Approach and the Radial Septum-Understanding the Anatomy and Improving Volar Exposure for Distal Radius Fractures: Imagine What You Could Do With an Extra Inch. Tech Hand Up Extrem Surg. 2016 Dec; 20(4):155-160.
View in:
PubMed
Reply to C. Shah et al. J Clin Oncol. 2016 05 20; 34(15):1824-5.
View in:
PubMed
Estimating treatment effect in a proportional hazards model in randomized clinical trials with all-or-nothing compliance. Biometrics. 2016 09; 72(3):742-50.
View in:
PubMed
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373(21):2005-14.
View in:
PubMed
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015 Nov 20; 33(33):3938-44.
View in:
PubMed
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20; 32(27):2959-66.
View in:
PubMed
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol. 2014 Sep 10; 32(26_suppl):36.
View in:
PubMed
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8.
View in:
PubMed
Reply to S. Goteti et al. J Clin Oncol. 2014 Mar 10; 32(8):856.
View in:
PubMed
Marker Sequential Test (MaST) design. Clin Trials. 2014 Feb; 11(1):19-27.
View in:
PubMed
An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials. 2013 Oct; 10(5):754-60.
View in:
PubMed
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15; 105(10):701-10.
View in:
PubMed
Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol. 2013 Sep 01; 31(25):3158-61.
View in:
PubMed
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
View in:
PubMed
Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood. 2013 Jan 03; 121(1):156-8.
View in:
PubMed
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013 Mar 15; 119(6):1140-8.
View in:
PubMed
TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):751-7.
View in:
PubMed
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92.
View in:
PubMed
Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials. Clin Trials. 2012 Apr; 9(2):155-63.
View in:
PubMed
The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012 Sep 01; 106(3):254-9.
View in:
PubMed
The impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy. J Clin Oncol. 2011 Sep 20; 29(27_suppl):96.
View in:
PubMed
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011 Nov 15; 17(22):7194-203.
View in:
PubMed
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials. 2011 Oct; 8(5):591-600.
View in:
PubMed
Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2012 Feb; 109(4):596-602.
View in:
PubMed
When bad things happen to good studies. J Clin Oncol. 2011 Sep 10; 29(26):3497-9.
View in:
PubMed
Effect of lattice structure on energetic electron transport in solids irradiated by ultraintense laser pulses. Phys Rev Lett. 2011 May 06; 106(18):185004.
View in:
PubMed
An audit strategy for progression-free survival. Biometrics. 2011 Sep; 67(3):1092-9.
View in:
PubMed
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011 Jan; 6(1):103-8.
View in:
PubMed
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47.
View in:
PubMed
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010; 12(3):R26.
View in:
PubMed
Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics. 2010 Oct; 11(4):676-92.
View in:
PubMed
A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials. 2010 Jun; 7(3):197-208.
View in:
PubMed
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7693-7700.
View in:
PubMed
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Nov 10; 27(32):5319-24.
View in:
PubMed
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009 Dec 10; 27(35):5958-64.
View in:
PubMed
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009 Oct 20; 27(30):4966-72.
View in:
PubMed
Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol. 2009 Sep 01; 27(25):e82-3; author reply e84.
View in:
PubMed
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009 May 15; 69(10):4184-91.
View in:
PubMed
Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med. 2008 Nov 29; 27(27):5709-24.
View in:
PubMed
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5.
View in:
PubMed
Weighted analyses for cohort sampling designs. Lifetime Data Anal. 2009 Mar; 15(1):24-40.
View in:
PubMed
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 01; 26(25):4063-71.
View in:
PubMed
Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008 Jul 15; 14(14):4368-71.
View in:
PubMed
Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clin Cancer Res. 2008 Jun 01; 14(11):3427-33.
View in:
PubMed
Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. J Clin Oncol. 2008 May 20; 26(15_suppl):557.
View in:
PubMed
Sensitivity analysis of progression-free survival with dependent withdrawal. Stat Med. 2008 Apr 15; 27(8):1180-98.
View in:
PubMed
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008 Mar 01; 14(5):1407-12.
View in:
PubMed
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5.
View in:
PubMed
Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol. 2007 Nov 01; 25(31):5019-23.
View in:
PubMed
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007 May 20; 25(15):2127-32.
View in:
PubMed
Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol. 2007 May 20; 25(15):2122-6.
View in:
PubMed
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14; 355(24):2542-50.
View in:
PubMed
Bayesian modeling approach to examining heterogeneity in censored survival analysis. Biometrics. 2006 Jun; 62(2):623; author reply 623-4.
View in:
PubMed
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9.
View in:
PubMed
A method for analyzing disease-specific mortality with missing cause of death information. Lifetime Data Anal. 2006 Mar; 12(1):35-51.
View in:
PubMed
Generalized rank tests for replicated microarray data. Stat Appl Genet Mol Biol. 2005; 4:Article3.
View in:
PubMed
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72.
View in:
PubMed
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res. 2004 Feb 15; 10(4):1206-11.
View in:
PubMed
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2003 Oct; 42(1):79-86.
View in:
PubMed
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26.
View in:
PubMed
Weighted estimating equations for linear regression analysis of clustered failure time data. Lifetime Data Anal. 2003 Jun; 9(2):123-38.
View in:
PubMed
Optimal weight functions for marginal proportional hazards analysis of clustered failure time data. Lifetime Data Anal. 2002 Mar; 8(1):5-19.
View in:
PubMed
Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001; (30):44-51.
View in:
PubMed
Estimation of regression parameters and the hazard function in transformed linear survival models. Biometrics. 2000 Jun; 56(2):571-6.
View in:
PubMed
On tests for group variation with a small to moderate number of groups. Lifetime Data Anal. 1998; 4(2):139-48.
View in:
PubMed
Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997 Dec; 64(6):1686-93.
View in:
PubMed
Spline-based tests in survival analysis. Biometrics. 1994 Sep; 50(3):640-52.
View in:
PubMed
A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. Biometrics. 1994 Mar; 50(1):244-53.
View in:
PubMed
Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics. 1990 Mar; 46(1):93-102.
View in:
PubMed
A linear rank test for use when the main interest is in differences in cure rates. Biometrics. 1989 Sep; 45(3):899-904.
View in:
PubMed